Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
, 15 (30), 3814-6

Adalimumab in Ulcerative Colitis: Two Cases of Mucosal Healing and Clinical Response at Two Years

Affiliations
Case Reports

Adalimumab in Ulcerative Colitis: Two Cases of Mucosal Healing and Clinical Response at Two Years

Manuel Barreiro-de Acosta et al. World J Gastroenterol.

Abstract

Infliximab (IFX) is currently the only biologic therapy used in the treatment of moderate-to-severe ulcerative colitis (UC). In the years to come, more biologic therapies will have a role in the management of moderate-to-severe UC. We report on two patients with steroid-dependent UC who, due to adverse reactions to IFX, have been under therapy with adalimumab for two years. Both patients received concomitant immunosuppressive treatment. Long term clinical remission and mucosal healing are described.

Figures

Figure 1
Figure 1
Colonoscopy. A: Case 1 at 2 years of adalimumab treatment; B: Case 2 at 2 years of adalimumab treatment.

Similar articles

See all similar articles

Cited by 8 PubMed Central articles

See all "Cited by" articles

Publication types

Feedback